Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe
Company expands breast specimen imaging portfolio and leadership in
breast cancer diagnosis and care
MARLBOROUGH, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/breastbiopsies?src=hash” target=”_blank”gt;#breastbiopsieslt;/agt;–Hologic, Inc. (Nasdaq: HOLX) today announced global commercial
availability of the Trident® HD specimen radiography system,
a next-generation solution that delivers enhanced image quality,
improved workflow and instant sample verification during
breast-conserving surgeries and stereotactic breast biopsies.1
The Trident products are the only specimen radiographs on the market to
use amorphous selenium direct capture imaging – the same detector
technology used in Hologic’s 3Dimensions™ mammography system – to
generate crisp, clear, high-resolution images. The new Trident HD
system, which recently received FDA clearance in the US and a CE Mark in
Europe, also features a bigger detector that allows for complete imaging
of larger breast surgical specimens, along with a wide range of surgical
and biopsy samples.2
“The Trident HD system is a breakthrough solution that delivers the
superior image quality clinicians have come to expect from Hologic
products, helping to streamline workflows and reduce recalls while
decreasing procedure times,” said Pete Valenti, Hologic’s Division
President, Breast and Skeletal Health Solutions. “We are committed to
identifying and addressing the challenges of our customers and their
patients at every step of the breast health journey, and our expanding
product portfolio is evidence of that commitment.”
The Trident HD system eliminates the need for clinicians to transport
specimens for imaging and features an ergonomic design that is 37
percent smaller than the original Trident system, making it easy to
maneuver in a crowded operating or procedure room. Prior mammography or
biopsy images can be displayed on the same Trident HD high-resolution
monitor to speed comparison and analysis, resulting in reduced procedure
time and improved workflow.1 Additionally, an intuitive
touchscreen interface and wireless integration supports advanced image
sharing and seamless transfer of patient records to the facility’s
picture archiving and communication system (PACS).
The market leader in mammography, Hologic has expanded its product suite
significantly in recent months through insight-driven, innovative
product launches and strategic acquisitions to address the continuum of
breast health care. In addition to the Trident HD system, Hologic
recently added the LOCalizer™ wireless radio frequency identification
(RFID) breast lesion surgical guidance system, which is available in the
U.S. and Europe. The Company also offers the BioZorb® 3D
bioabsorbable marker, an implantable three-dimensional marker that
enables more targeted radiation therapy and helps clinicians overcome
challenges in breast-conserving surgery or lumpectomy. BioZorb is
currently available in the U.S. only. This expanded portfolio enables
Hologic to play a larger role in breast-conserving surgery and further
strengthen its offerings to radiologists, pathologists and breast
surgeons.
For more information about the Trident HD system, please visit here.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily
focused on improving women’s health and well-being through early
detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, 3D, 3D Mammography, 3Dimensions, BioZorb, and Trident are
trademarks and/or registered trademarks of Hologic, Inc., and/or its
subsidiaries in the United States and/or other countries. Hologic is an
exclusive distributor and licensee of the LOCalizer product and
trademark, which is manufactured by Health Beacons.
Forward-Looking Statements
This news release may contain forward-looking information that involves
risks and uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated in
any particular manner with respect to an individual patient, as the
actual effect of the use of the products can only be determined on a
case-by-case basis. In addition, there can be no assurance that these
products will be commercially successful or achieve any expected level
of sales. Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or statements
are based.
This information is not intended as a product solicitation or promotion
where such activities are prohibited. For specific information on what
products are available for sale in a particular country, please contact
a local Hologic sales representative or write to womenshealth@hologic.com.
SOURCE: Hologic, Inc.
1 Wilson A. Trident 2.0 QUAL Qualitative Findings. Explore
and identify the ideal breast biopsy verification system from the OR.
Kadence International. July 2016.
2 Compared to original
Trident system, which is not available in Europe
Contacts
Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978
(mobile)
jane.mazur@hologic.com
Investor
Contact:
Michael Watts
858.410.8588
michael.watts@hologic.com
